Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Trapped in a regulation labyrinth: The case of the Indian me...

Dinar Kale discusses the medical device industry in India in the first of a two part article, part two of which will be published next week. In part one Dinar addresses the impact of the lack of regulation in this space. In the last decade the Indian pharmaceutical industry has emerged as a leading supplier of generic drugs to developing and...

Articles

An integrated approach to biosimilar development and commerc...

Deepa Dahal provides thoughts on the future of the biosimilar industry with respect to market access, our theme on pharmaphorum this month. Over the next 10 – 15 years, the biosimilars industry is expected to explode as the patents on branded biologics begin to expire.

Articles

The future of healthcare? Kill the bugs save the world! Part...

Trevor Lewis shares his thoughts on the future of healthcare, including drug resistance, which is potentially a major threat to human health. This is a story about possible good news and bad news, it is a scary ride but offers some hope for us all...failure is not acceptable and success is required for survival...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.